Showing results (121-130 of 200) with videos related to

Sort By:
Pageof 20
Trials|February 13, 2022
Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II studyDaisuke Hashimoto, Sohei Satoi, Hideki Ishikawa, et al.
Surgery Today|August 24, 2016
Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carcinomaHidetoshi Nitta, Shigeki Nakagawa, Takayoshi Kaida, et al.
Pancreas|March 12, 2016
Heterogeneity of KRAS Mutations in Pancreatic Ductal AdenocarcinomaDaisuke Hashimoto, Kota Arima, Naomi Yokoyama, et al.
Anticancer Research|April 12, 2015
Scoring system based on tumor markers and Child-Pugh classification for HCC patients who underwent liver resectionShigeki Nakagawa, Hiromitsu Hayashi, Hidetoshi Nitta, et al.
Annals of Surgical Oncology|May 21, 2014
Clinicopathological and prognostic significance of preoperative serum zinc status in patients with hepatocellular carcinoma after initial hepatectomyKatsunori Imai, Toru Beppu, Takanobu Yamao, et al.
Surgical Case Reports|October 18, 2017
A long-term survivor of hilar cholangiocarcinoma with resection of recurrent peritoneal dissemination after R0 surgery: a case reportTatsunori Miyata, Hirohisa Okabe, Akira Chikamoto, et al.
Anticancer Research|December 1, 2017
Predictors of Cure of Intrahepatic Cholangiocarcinoma After Hepatic ResectionMasayo Tsukamoto, Yo-Ichi Yamashita, Katsunori Imai, et al.
World Journal of Surgery|September 10, 2017
The Prognostic Impact of Controlling Nutritional Status (CONUT) in Intrahepatic Cholangiocarcinoma Following Curative Hepatectomy: A Retrospective Single Institution StudyTatsunori Miyata, Yo-Ichi Yamashita, Takaaki Higashi, et al.
Plos One|August 2, 2014
EZH2 is associated with malignant behavior in pancreatic IPMN via p27Kip1 downregulationHideyuki Kuroki, Hiromitsu Hayashi, Hirohisa Okabe, et al.
Annals of Surgical Oncology|October 21, 2024
Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable Pancreatic Ductal AdenocarcinomaDaisuke Hashimoto, Sohei Satoi, So Yamaki, et al.
Pageof 20